744666
Last Update Posted: 2009-08-06
Recruiting status is unknown
All Genders accepted | 18 Years + |
70 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids
Intravitreal triamcinolone acetonide (IVTA) is a commonly employed treatment for various vitreoretinal disorders. However, approximately 23% to 50% of patients who receive IVTA develop ocular hypertension after the drug is injected into the eye. Similar to IVTA, topically administered corticosteroids eye drops result in ocular hypertension in approximately 33% of the population. It is unknown whether identifying patients who develop ocular hypertension from topical corticosteroids could be used to identify patients who are at risk for injectable IVTA. Therefore, the purpose of this study is to evaluate the efficacy of topical prednisolone 1% four times daily for one month as a screening test to reduce the incidence and severity of ocular hypertension after IVTA injection.
Eligibility
Relevant conditions:
Vitreoretinal Disease
Ocular Hypertension
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Contact Information
Overall Contact
Kenneth Eng, MD, FRCSC
kt_eng@hotmail.com
416-480-4468
Jeffery Gale, MD, FRCSC
jeffgaleuwo@yahoo.com
613-544-3400
Data sourced from ClinicalTrials.gov